Question 1

What specific drugs are considered dysbiosis-inducing?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients clinical trial (NCT07191171). Contact the study team or your healthcare provider for specific answers.

Question 2

How might my gut health influence my response to immunotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients clinical trial (NCT07191171). Contact the study team or your healthcare provider for specific answers.

Question 3

What data will be collected during this study, and how will it be used?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients clinical trial (NCT07191171). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any risks associated with participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients clinical trial (NCT07191171). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the potential benefits of participating in this research?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients clinical trial (NCT07191171). Contact the study team or your healthcare provider for specific answers.

What this study is about